The history of the tetracyclines

Annals of the New York Academy of Sciences

Volumn 1241, Issue 1, 2011, Pages 17-32

  Nelson, Mark L ^a   Levy, Stuart B ^a,b  

^a Transcept Pharmaceuticals Inc   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bioactivity; History; Mechanism; Resistance; Tetracyclines; Uses

Indexed keywords

AMPHOLYTE; CHLORTETRACYCLINE; DEMECLOCYCLINE; DOXYCYCLINE; METACYCLINE; MINOCYCLINE; NAPHTHACENE DERIVATIVE; OMADACYCLINE; OXYTETRACYCLINE; PENICILLIN G; STREPTOMYCIN; TETRACYCLINE; TIGECYCLINE;

ACTINOBACTERIA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; APPENDIX PERFORATION; ARTICLE; BIOLOGY; COMMUNITY ACQUIRED PNEUMONIA; DRUG ACTIVITY; DRUG DEVELOPMENT; DRUG MECHANISM; GENETIC ENGINEERING; HUMAN; LOW DRUG DOSE; MALARIA; MEDICAL RESEARCH; PERIODONTITIS; REPRESSOR GENE; ROCKY MOUNTAIN SPOTTED FEVER; SCIENTIFIC LITERATURE; STRUCTURE ACTIVITY RELATION; TRANSPOSON; ULTRAVIOLET SPECTROSCOPY;

EID: 84255195560     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2011.06354.x     Document Type: Article

References (104)

1. From an interview conducted by author Mark Nelson in April, 2011 with Mr. Tobey Hockett, aged 68, now retired after a successful career as an attorney and Chief Assistant Public Defender in Sarasota, Florida
2. Pearson, M. 1969. The Million Dollar Bugs. G.P. Putnam's Sons. New York
3. Dubos, R.J. & R.D. Hotchkiss 1941. The production of bacteriocidal substances by aerobic sporulating bacilli. J. Exp. Med. 78: 629-640.
4. Waksman, S.A., A. Schatz & D.M. Reynolds 1946. Production of antibiotic substances by actinomycetes. Ann. N.Y. Acad. Sci. 48: 73-85.
5. Duggar, B.M. 1948. Aureomycin: a product of the continuing search for new antibiotics. Ann. N.Y. Acad. Sci. 51: 177-181.
6. Finlay, A.C., G.L. Hobby, S.Y. Pan, et al 1950. Terramycin, a new antibiotic. Science 111: 85.
7. King, E.Q., C.N. Lewis, H. Welch, et al 1950. Clinical observations on the use of Terramycin hydrochloride. J. Am. Med. Assoc. 143: 1-4.
8. Stephens, C.R., L.H. Conover, F.A. Hochstein, et al 1952. Terramycin. VIII. Structure of Aureomycin and Terramycin. J. Am. Chem. Soc. 74: 4976-4977.
9. Stephens, C.R., L.H. Conover, R. Pasternak, et al. 1954. The structure of Aureomycin. J. Am. Chem. Soc. 76: 3568-3575.
10. Conover, L.H., W.T. Moreland, A.R. English, et al 1953. Terramycin. XI. Tetracycline. J. Am. Chem. Soc. 75: 5455.
11. Blackwood, R.K., J.J. Beereboom, H.H. Rennhard, et al 1961. 6-Methylenetetracyclines. I. A new class of antibiotics. J. Am. Chem. Soc. 83: 2773-2774.
12. Stephens, C.R., J.J. Beereboom, H.H. Rennhard, et al 1963. 6-Deoxytetracyclines. IV. Preparation, C-6 stereochemistry, and reactions. J. Am. Chem. Soc. 85: 2643-2652.
13. Dahl, E.L. & P.J. Rosenthal 2007. Multiple antibiotics exert delayed effects against thePlasmodium falciparumapicoplast.Antimicrob. Agents Chemother. 51: 3485-3490.
14. Hoerauf, A., S. Mand, O. Adjei, et al 2001. Depletion of wolbachia endobacteria inOnchocerca volvulusby doxycycline and microfilaridermia after ivermectin treatment. Lancet 357: 1415-1416.
15. McCormick, J.R.D., N.O. Sjolander, U. Hirsch, et al 1957. A new family of antibiotics: the demethyltetracyclines. J. Am. Chem. Soc. 79: 4561-4563.
16. Church, R.F., R.E. Schaub & M.J. Weiss 1971. Synthesis of 7-dimethylamino- 6-demethyl-6-deoxytetracycline (Minocycline) via 9-nitro-6-demethyl-6- deoxytetracycline. J. Org. Chem. 36: 723-725.
17. Doershuk, A.P., B.A. Bitler & J.R.D. McCormick 1955. Reversible isomerization in the tetracycline family. J. Am. Chem. Soc. 77: 4687.
18. Roberts, M.C. 2003. Tetracycline therapy: Update. Clin. Infect. Dis. 36: 462-467.
19. Nelson, M.L. & M.Y. Ismail 2007. The antibiotic and nonantibiotic tetracyclines. In Comprehensive Medicinal Chemistry, Vol 7. D. Triggle & J. Taylor, Eds.: 742-775. Elsevier Science Press. Ltd., New York
20. Rogalski, W. 1985. The tetracyclines, 1985. InThe Handbook of Experimental Pharmacology. 1985. Vol 78. R.K. Blackwood, J.J. Hlavka, J.H. Boothe, Eds.: 117-198. Springer-Verlag, Berlin. New York
21. Bryskier, A. 2005. Structure-activity relationships in antibacterial agents. In Antimicrobial Agents: Antibacterials and Antifungals. Tetracyclines. A. Bryskier, Ed.: 1371-1377. ASM Press. Washington, DC
22. Weinstein, L. 2005. Antimicrobial agents: protein synthesis inhibitors and miscellaneous antibacterial agents. In Goodman and Gilman's: The Pharmacological Basis of Therapeutic Agents, 11th Ed L.L. Brunton, J.S. Lazo, & K.L. Parker, Eds.: 562-590. McGraw-Hill Companies. New York
23. Gale, E.F. & J.P. Folkes 1953. The assimilation of amino-acids by bacteria. XV. Actions of antibiotics on nucleic acid and protein synthesis inStaphylococcus aureus. Biochem. J. 53: 493-498.
24. Connamacher, R.H. & H.G. Mandel 1965. Binding of tetracycline to the 30S ribosomes and to polyuridylic acid. Biochem. Biophys. Res. Comm. 20: 98-103.
25. Strel'tsov, S.A., M.K. Kukhanova, G.V. Gurskii, et al 1975. Oxytetracycline binding toE. coliribosomes. Mol. Biol. 9: 910-921.
26. Day, L.E. 1966. Tetracycline inhibition in cell-free protein synthesis. I. Binding of tetracyclines to components of the system. J. Bact. 91: 1917-1923.
27. Goldman, R.A., T. Hasan, C.C. Hall, et al 1983. Photoincorporation of tetracycline intoEscherichia coliribosomes. Identification of the major proteins photolabeled by native tetracycline and tetracycline photoproducts and implications for the inhibitory action of tetracycline on protein synthesis. Biochemistry 22: 359-368.
28. Epe, B. & P. Woolley 1984. The binding of 6-demethylchlortetracycline to 70S, 50S, and 30S ribosomal particles: a quantitative study by fluorescence anisotropy. EMBO J. 3: 121-126.
29. Tritton, T.R. 1977. Ribosome-tetracycline interactions. Biochemistry 16: 4133-4138.
30. Gottesman, M.E. 1967. Reaction of the ribosome-bound peptidyltransfer ribonucleic acid with aminoacyl transfer ribonucleic acid or puromycin. J. Biol. Chem. 242: 5564-5571.
31. Craven, G.R., R. Gavin & T. Fanning 1969. The transfer RNA binding site on the 30S ribosome and the site of tetracycline inhibition. Cold Spring Harbor Symp. Quant. Biol. 34: 129-134.
32. Suarez, G. & D. Nathans 1965. Inhibition of aminoacyl tRNA binding to ribosomes by tetracycline. Biochem. Biophys. Res. Comm. 18: 743-750.
33. Smythies, J.R., F. Bennington & R.D. Morin 1972. On the molecular mechanism of action of the tetracyclines. Experentia 28: 1253-1254.
34. Moazed, D. & H.F. Noller 1987. Interaction of antibiotics with functional sites in 16S ribosomal RNA. Nature 327: 389-394.
35. Brodersen, D.E., W.M. Clemons, Jr., A.P. Carter, et al 2000. The structural basis for the action of the antibiotics tetracycline, pactamycin and hygromycin B on the 30S ribosomal subunit. Cell 103: 1143-1154.
36. Chopra, I. & S.J. Eccles 1977. Diffusion of tetracycline across the outer membrane ofEschericia coliK-12: involvement of protein Ia. Biochem. Biophys. Res. Comm. 83: 550-557.
37. Oliva, B., G. Gordon, P. McNicholas, et al 1992. Evidence that tetracycline analogs whose primary target is not the bacterial ribosome cause lysis ofEschericia coli. Antimicrob. Agents Chemother. 36: 913-919.
38. Hughes, L.J., J.J. Stezowski & R.E. Hughes 1979. Chemical-structural properties of the tetracycline derivatives. 7. Direct evidence for the coexistence of the zwitterionic and non-ionized forms of the free base in solution. J. Am. Chem. Soc. 101: 7655-7657.
39. Othersen, O.G., A.C. Beierlein, H. Lanig & T. Clark 2003. Conformations and tautomers of tetracycline. J. Phys. Chem. B 107: 13743-13749.
40. Schmitt, M.O., S. Schneider & M.L. Nelson 2007. Novel-Insight into the protonation-deprotonation equilibria of tetracycline and several derivatives in aqueous solution II. Analysis of the pH-dependent fluorescence spectra by the SVD technique. Zeits. Phys. Chem. 221: 235-271.
41. Demerec, C.M. 1949. Patterns of bacterial resistance to penicillin, aureomycin, and streptomycin. J. Clin. Invest. 28: 891-893.
42. Agata, A. & R. Monaco 1954. Crossed resistance to tetracycline of various chloramphenicol-resistantShigellastrains and of various terramycin-resistantSalmonella typhosastrains. Boll. Della Soc. Ital. Biol. Sper. 30: 713-715.
43. Levy, S.B. & L. McMurry 1974. Detection of an inducible membrane protein associated with R-factor mediated tetracycline resistance. Biochem. Biophys. Res. Comm. 56: 1060-1068.
44. McMurry, L., R. Petrucci & S.B. Levy 1980. Active efflux of tetracycline encoded by four genetically different resistant determinants inE. coli. Proc. Natl. Acad. Sci. USA 77: 3974-3977.
45. Nikaido, H. 2009. Multidrug resistance in bacteria. Annu. Rev. Biochem. 78: 119-146.
46. Burdett, V. 1986. Streptococcal tetracycline resistance mediated at the level of protein synthesis. J. Bact. 165: 564-569.
47. Nikolich, M.P., N.B. Shoemaker & A.A. Salyers 1992. A Bacteroides tetracycline resistance gene represents a new class of ribosomal protection tetracycline resistance. Antimicrob. Agents Chemother. 36: 1005-1012.
48. Taylor, D.E. & A. Chau 1996. Tetracycline resistance mediated by ribosomal protection. Antimicrob. Agents Chemother. 40: 1-5.
49. M.C. Roberts 2005. Tetracycline resistance due to ribosomal protection proteins. In Frontiers in Antimicrobial Resistance, A Tribute to Stuart B. Levy. D.G. White, M.N. Alekshun, P.F. McDermott, Eds.: 19-28. ASM Press. Washington, DC
50. Yang, W. & I.F. Moore, K.P. Koteva, et al 2004. TetX is a flavin-dependent monooxygenase conferring resistance to tetracycline antibiotics. J. Biol. Chem. 279: 52346-52352.
51. Levy, S.B., L.M. McMurry, et al 1999. Nomenclature for new tetracycline resistance determinants. Antimicrob. Agents Chemother. 43: 1523-1524.
52. Hillen, W., G. Klock, I. Kaffenberger, et al 1982. Purification of the TET repressor and TET operator from the transposons Tn10 and characterization of their interaction. J. Biol. Chem. 252: 6605-6013.
53. Orth, P., F. Cordes, D. Schnappinger, et al 1998. Conformational changes of the Tet repressor induced by tetracycline trapping. J. Mol. Biol. 279: 439-447.
54. Okusu, H., D. MA & H. Nikaido 1996. ActAB efflux pump plays a major role in the antibiotic resistance phenotype ofEschericia colimultiple-antibiotic reistance (Mar) mutants. Mol. Microbiol. 6: 1323-1333.
55. Nikaido, H. 2005. Role, structure, and function of multidrug efflux pumps in Gram-negative bacteria. In Frontiers in Antimicrobial Resistance, A Tribute to Stuart B. Levy D.G. White, M.N. Alekshun, P.F. McDermott, Eds: 261-274. ASM Press. Washington, DC
56. Poole, K. 2005. Pseudomonas aeruginosa. In Frontiers in Antimicrobial Resistance, A Tribute to Stuart B. Levy D.G. White, M.N. Alekshun, P.F. McDermott, Eds.: 355-366. ASM Press. Washington, DC
57. Bassett, E.J., M.S. Keith, G. Armelagos, et al 1980. Tetracycline-labeled human bone from ancient Sudanese Nubia (A. D. 350). Science 209: 1532-1534.
58. Frost, H.M., A. Villanueva, H. Roth & S. Stanislavecic 1961. Experimental multiband tetracycline measurements of lamellar osteosblastic activity. Henry Ford Hosp. Med. Bull. 9: 312-319.
59. Keith, M. & G.J. Armelagos 1983. Naturally occurring dietary antibiotics and human health. In The Anthropology of Medicine, 1st Ed. L. Romannuci-Ross, D. Moerman & R.R. Tancredi, Eds.: 63-74 Preager Press. New York
60. Nelson, M.L., A. Dinardo, J. Hochberg & G. Armelagos 2010. Mass spectroscopic characterization of tetracycline in the skeletal remains of an ancient population from Sudanese Nubia, 350-550 CE. Am. J. Phys. Anthropol. 143: 151-154.
61. Cook, M., E.L. Molto & C. Andersen 1989. Fluorochrome labeling in Roman period skeletons from Dakleh Oaisis, Egypt. Am. J. Phys. Anthropol. 80: 137-143.
62. Sum, P.E., V.J. Lee, R.T. Testa, et al 1994. Glycylcyclines. I. A new generation of potent antibacterial agents through modification of the 9-aminotetracyclines. J. Med. Chem. 37: 184-188.
63. Sum, P.E. & P. Petersen 1999. Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936. Bioorg. Med. Chem. Lett. 9: 1459-1462.
64. Dowzicky, M.J. & E. Chmelarova 2011. Globalin vitroactivity of tigecycline and linezolid against Gram positive organisms collected between 2004-2009. Int. J. Antimicrob. Agents 37: 562-566.
65. Sader, H.S., J.D. Farrell & R.N. Jones 2011. Tigecycline activity tested against multidrug resistant Enterobacteriaceae and Acinetobacter spp. isolated in US medical centers (2005-2009). Diagn. Microb. Infect. Dis. 69: 223-227.
66. Townsend, M.L., M.W. Pound & R.H. Drew 2011. Potential role of tigecycline in the treatment of community-acquired bacterial pneumonia. Infect. Drug Res. 4: 77-86.
67. Jump, R.L., Y. Li, M.J. Pultz, et al 2011. Tigecycline exhibits inhibitory activity againstClostridium difficilein the colon of mice and does not promote growth or toxin production. Antimicrob. Agents Chemother. 55: 546-549.
68. Nelson, M.L, B.H. Park & S.B. Levy 1994. Molecular requirements for the inhibition of the tetracycline antiport protein and the effect of potent inhibitors on the growth of tetracycline-resistant bacteria. J. Med. Chem. 37: 1355-1361.
69. Nelson, M.L. & S.B. Levy 1999. Reversal of tetracycline resistance mediated by different tetracycline efflux determinants by an inhibitor of the Tet(B) antiport protein. Antimicro. Agents Chemother. 43: 1719-1724.
70. Nelson, M.L., M.Y. Ismail, L. McIntyre, et al 2003. Versatile and facile synthesis of diverse semi-synthetic tetracycline derivatives via Pd-catalyzed reactions. J. Org. Chem. 68: 5838-5851.
71. Bhatia, B., T. Bowser, J. Chen, et al 2003. PTK 0796 (BAY 73-6944) and other novel tetracycline derivatives exhibiting potentin vitroandin vivoactivities against antibiotic resistant Gram-positive bacteria, abstr. 2420.43rd Intersci. Conf. on Antimicrob. Agents and Chemother, September 13-17. Chicago, IL
72. Arbeit, R.D., J.A. Roberts, A.R. Forsythe, et al 2010. Safety and efficacy of PTK 0796: results of the phase 2 study in complicated skin and skin structure infections following IV and oral step-down therapy, abstr. 2420. 48th Intersci. Conf. on Antimicrob. Agents and Chemother, September 12-15. Washington, DC
73. Hastings, M.L., J. Berniac, Y.H. Liu, et al 2009. Tetracyclines that promote SMN2 exon 7 splicing as therapeutics for spinal muscular atrophy. Sci. Trans. Med. 5: 1-7.
74. Charrest, M.G., C.D. Lerner, J.D. Brubaker, et al 2005. A convergent enantioselective route to structurally diverse 6-deoxytetracycline antibiotics. Science 308: 395-398.
75. Korst, J.J., J.D. Johnston, K. Butler, et al 1968. The total synthesis of dl-6-demethyl-6-deoxytetracycline. J. Am. Chem. Soc. 90: 439-457.
76. Martin, W., H. Hartung, H. Urbach & W. Drueckhimer 1973. Synthesis in the tetracycline series. I. Total synthesis of dl-7-chloro-6-deoxytetracyclines and dl-7- chloro-6-demethyl-6deoxytetracyclines of the natural, the 5a-epi, and the 6-epi series. Tet. Lett. 36: 3513-3516.
77. Kirchlechner, R. & W. Rogalski 1980. Synthesis of 6-thiatetracycline, a highly active analog of the antibiotic tetracycline. Tet. Lett. 21: 247-250.
78. Clark, R., X. Xiao, D. Hunt, et al 2010. Fluorocyclines: A new class of broad-spectrum tetracyclines with antibacterial properties, abstr. F1-2155. 51st Intersci. Conf. on Antimicrob. Agents and Chemother, September 17-20. Chicago, IL.
79. Gossen, M. & H. Bujard 1992. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA 89: 5547-5551.
80. Bujard, H. 1998. The use of genetic switches for the generation of conditional mutants at the level of cells and animals. NATO ASI Series, Cell Biol. 105: 45-52.
81. Baron, U. & H. Bujard 2000. Tet repressor-based system for regulated gene expression in eukaryotic cells: principles and advances. Methods Enzymol. 327: 401-421.
82. Furth, P.A., L. St. Onge, H. Boger, et al 1994. Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter. Proc. Natl. Acad. Sci. USA 91: 9302-9306.
83. Gossen, M. 2010. Tet technology and drug discovery. Eur. Biopharm. Rev. 38: 34-38.
84. Bertram, R. & W. Hillen 2008. The application of the Tet repressor in prokaryotic gene regulation and expression. Microb. Biotech. 1: 2-16.
85. Zhu, P., M.I. Aller, U. Baron, et al 2007. Silencing and Un-silencing of tetracycline-controlled genes in neurons. PLoS One 2: 6-12.
86. Golub, L.M., H.M. Lee, G. Lehrer, et al 1983. Minocycline reduces gingival collagenolytic activity during diabetes: preliminary observations and a proposed new mechanism of action. J. Periodont. Res. 18: 516-521.
87. Greenwald, R.A., L.M. Golub, B. Lavietes, et al 1987. Minocycline inhibits rheumatoid synovial collagenasein vivoandin vitro. J. Rheumatol. 14: 28-32.
88. Hanemaaijer, R., T. Sorsa, Y. Kontrinen, et al 1997. MMP-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells. J. Biol. Chem. 272: 31504-31509.
89. Golub, L.M. & R.T. Evans, T.F. McNamara, et al 1994. A non-antimicrobial tetracycline inhibits gingival matrix metalloproteinases and bone loss inPorphrymonas gingivitis-induced periodontitis in rats. Ann. N.Y. Acad. Sci. 732: 96-111.
90. Griffin, M., E. Fricovsky, G. Ceballos & F. Villareal 2010. Tetracyclines: a pleiotropic family of compounds with promising therapeutic properties. Review of the literature. Am. J. Physiol. Cell Physiol. 299: C539-C548.
91. Higgins, P.J., M. Draper & M. Nelson 2011. Antiinflammatory activity of tetracyclines: applications to human disease. Antiinflam. AntiAllerg. Agents Med. Chem. 10: 132-152.
92. Curci, J., D. Mao, D. Bohner, et al 2000. Postoperative treatment with doxycycline reduces aortic wall expression and activation of MMPs in patients with abdominal aortic aneurysms. J. Vasc. Surg. 31: 325-242.
93. Leonard, C., A. Hall, L. Collier, et al 2009. Inhibition of gelatinase activity reduces neural injury in anex vivomodel of hypoxia-ischemia. Neuroscience 160: 755-766.
94. Kim, T. & O. Hwang 2009. Doxycycline is neuroprotective against nigral dopaminergic degeneration by a dual mechanism involving MMP-3. Neurotox. Res. 56: 671-668.
95. Ryan, M., A. Usman, N. Ramamurthy, et al 2001. Excessive MMP activity in diabetes: inhibition by tetracycline analogs with zinc reactivity. Curr. Med. Chem. 8: 305-316.
96. Tikka, T., B. Feibich, G. Goldsteins, et al 2001. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxcity by inhibiting activation and proliferation of microglia. J. Neurosci. 21: 2580-2588.
97. Solomon, A., M. Rosenblatt, D. Li, et al 2000. Doxycycline inhibition of IL-1 in corneal epithelium. Invest. Ophthamol. Vis. Sci. 41: 2544-2557.
98. Nessler, S., R. Dodel, A. Bittner, et al 2002. Effect of minocycline in experimental autoimmune encephalomyelitis. Ann. Neurol. 52: 689-690.
99. Madan, M., B. Bishayi, M. Hoge, et al 2007. Doxycycline affects diet and bacteria-associated atheriosclerosis in an ApoE heterozygote murine model: cytokine profiling implications. Atheriosclerosis 190: 62-72.
100. Tamargo, R., R. Bok & H. Brem 1991. Angiogenesis inhibition by minocycline. Cancer Res. 51: 672-675.
101. Zabad, R., L. Metz, T. Todoruk, et al 2007. The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: A pilot study. Mult. Scler. 13: 517-526.
102. Langevitz, P., I. Bank, D. Zemer, et al 1992. Treatment of resistant rheumatoid arthritis with minocycline: an open study. J. Rheumatol. 19: 1502-1504.
103. Hutchinson, M., B. Coats, S. Lewis, et al 2008. Proinflammatory cytokines oppose opioid-induced acute and chronic analgesia. Brain Behav. Immun. 22: 1178-1189.
104. Bilousova, T.V., L. Dansie M. Ngo, et al 2009. Minocycline promotes dendritic spine maturation and improves behavioral performance in the fragile X mouse. J. Med. Gen. 46: 94-102.